Danvers, MA-based Abiomed announced that the Impella 2.5, Impella CP and Impella 5.0 heart pumps received approval from India's Central Drugs Standard Control Organization for use during high-risk percutaneous coronary intervention, cardiogenic shock, and other reduced left ventricular function conditions. The first patient was treated with the Impella 2.5 heart...